National Quality Measures Clearinghouse | Measures by Topic: Melanoma

National Quality Measures Clearinghouse | Measures by Topic: Melanoma

Measures by Topic

Disease/Condition > Diseases (1520) > Neoplasms (175) > Neoplasms by Histologic Type (38) > Neoplasms, Germ Cell and Embryonal (28) > Neuroectodermal Tumors (28) > Neuroendocrine Tumors (28) >

Melanoma (28)

1-20 of 28   Next >
1. Melanoma: percentage of patient visits, regardless of age, seen with a new occurrence of melanoma who have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis. 2012 Nov. NQMC:008658 American Academy of Dermatology - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
2. Melanoma: percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within the 12 month period, into a recall system. 2012 Nov. NQMC:008657 American Academy of Dermatology - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
3. Melanoma: percentage of patients, regardless of age, with a new diagnosis of melanoma or a history of melanoma who received all of the specified follow-up aspects of care within the 12 month reporting period. 2012 Nov. NQMC:008656 American Academy of Dermatology - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
4. Melanoma: is the surgeon who performs sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma certified by the American Board of Surgery or equivalent board or international association? 2009 Nov. NQMC:007187 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
5. Melanoma: percentage of patients newly diagnosed with stage IV melanoma for whom a serum lactate dehydrogenase (LDH) level is measured. 2009 Nov. NQMC:007208 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
6. Melanoma: percentage of patients to undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom lymphoscintigraphy is performed to identify the draining nodal basin(s) when drainage to more than one basin is possible. 2009 Nov. NQMC:007194 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
7. Melanoma: percentage of patients treated for melanoma for whom stage-specific follow-up, including future skin exams, is discussed and documented. 2009 Nov. NQMC:007212 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
8. Melanoma: percentage of patients who have a resected primary melanoma metastatic to regional lymph nodes or distant sites for whom there is a documented discussion regarding adjuvant therapy. 2009 Nov. NQMC:007206 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
9. Melanoma: percentage of patients who have a stage Ib or II melanoma with whom sentinel lymph node biopsy (SLNB) is discussed. 2009 Nov. NQMC:007197 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
10. Melanoma: percentage of patients who have stages 0, I, or IIA melanoma for whom an abdominal CT/MRI, pelvic CT/MRI, or PET scan was not performed, except in response to specific signs or symptoms. 2009 Nov. NQMC:007207 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
11. Melanoma: percentage of patients who undergo a cervical lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 15 regional lymph nodes are resected and pathologically examined. 2009 Nov. NQMC:007199 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
12. Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are examined with serial sectioning/hematoxylin and eosin (HE) and with immunohistochemistry (IHC) if the HE analysis is negative or equivocal (i.e., S-100, HMB-45, and MART-1). 2009 Nov. NQMC:007196 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
13. Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are sent for permanent sectioning only (no frozen sections), unless a reason is documented. 2009 Nov. NQMC:007195 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
14. Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma for whom the pathology report documents the number of lymph nodes examined and the number of lymph nodes found to contain metastases. 2009 Nov. NQMC:007204 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
15. Melanoma: percentage of patients who undergo an axillary lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 10 regional lymph nodes are resected and pathologically examined. 2009 Nov. NQMC:007200 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
16. Melanoma: percentage of patients who undergo an inguinal lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least five regional lymph nodes are resected and pathologically examined. 2009 Nov. NQMC:007201 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
17. Melanoma: percentage of patients with a melanoma 1-2 mm thick (i.e., T2) for whom the surgical excision margins are 1-2 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted). 2009 Nov. NQMC:007192 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
18. Melanoma: percentage of patients with a melanoma for whom a clear histologic margin is documented.2009 Nov. NQMC:007190 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
19. Melanoma: percentage of patients with a melanoma for whom the pathology report documents Breslow thickness, Clark level, histologic ulceration, peripheral/radial and deep margin statuses, satellitosis, anatomic location of the lesion, regression, and mitotic rate. 2009 Nov. NQMC:007202 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
20. Melanoma: percentage of patients with a melanoma for whom the surgeon documented the measured surgical margin in the operative report. 2009 Nov. NQMC:007189 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected
1-20 of 28   Next > 21-28 of 28   < Previous 21. Melanoma: percentage of patients with a melanoma greater than or equal to 2 mm thick (i.e., T3 or T4) for whom the surgical excision margins are 2-3 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted). 2009 Nov. NQMC:007193 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 22. Melanoma: percentage of patients with a melanoma in situ (i.e., Tis) for whom the surgical excision margins are 5 mm (or the specific anatomic or cosmetic factors that limit margin distance are noted).2009 Nov. NQMC:007188 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 23. Melanoma: percentage of patients with a melanoma less than or equal to 1 mm thick (i.e., T1) for whom the surgical excision margins are 1 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted). 2009 Nov. NQMC:007191 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 24. Melanoma: percentage of patients with melanoma and clinically apparent/palpable lymphadenopathy for whom a lymph node dissection (LND) is performed without an antecedent histologic diagnosis. 2009 Nov. NQMC:007198 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 25. Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND). 2009 Nov. NQMC:007209 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 26. Melanoma: percentage of patients with melanoma who have a metastatic lymph node detected on sentinel lymph node biopsy (SLNB) for whom a complete lymph node dissection (CLND) is performed except in the context of a clinical trial or if the patient has severe comorbidities. 2009 Nov. NQMC:007210 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 27. Melanoma: percentage of patients with melanoma who have biopsy-proven, palpable nodal disease who do not undergo sentinel lymph node biopsy (SLNB). 2009 Nov. NQMC:007211 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 28. Melanoma: percentage of patients with melanoma who have clinically palpable nodal disease of the inguinofemoral nodes for whom a pelvic computed tomography (CT) or positron emission tomography (PET) is obtained to rule out pelvic lymphadenopathy. 2009 Nov. NQMC:007205 American College of Surgeons - Medical Specialty Society. View all measures by the developer(s) Compare Selected 21-28 of 28   < Previous